Skip to main content

Pfizer launches upstart with $103M, phase 3-ready drugs – FierceBiotech

By September 25, 2017News
pfizer-logo

pfizer-logo

In a first for the Big Pharma and as part of a new model, Pfizer is taking drugs from its shelves and licensing them to, while investing in, its SpringWorks Therapeutics startup.

{iframe}http://www.fiercebiotech.com/biotech/pfizer-launches-new-upstart-103m-phase-3-ready-meds{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.